20 results on '"Chung, Wen-Hung"'
Search Results
2. Immunophenotyping and Therapeutic Insights from Chronic Mucocutaneous Candidiasis Cases with STAT1 Gain-of-Function Mutations.
- Author
-
Lei, Wei-Te, Lo, Yu-Fang, Tsumura, Miyuki, Ding, Jing-Ya, Lo, Chia-Chi, Lin, You-Ning, Wang, Chuang-Wei, Liu, Lu-Hang, Shih, Han-Po, Peng, Jhan-Jie, Wu, Tsai-Yi, Chan, Yu-Pei, Kang, Chen-Xuan, Wang, Shang-Yu, Kuo, Chen-Yen, Tu, Kun-Hua, Yeh, Chun-Fu, Hsieh, Ya-Ju, Asano, Takaki, and Chung, Wen-Hung
- Abstract
Purpose: Heterozygous STAT1 Gain-of-Function (GOF) mutations are the most common cause of chronic mucocutaneous candidiasis (CMC) among Inborn Errors of Immunity. Clinically, these mutations manifest as a broad spectrum of immune dysregulation, including autoimmune diseases, vascular disorders, and malignancies. The pathogenic mechanisms of immune dysregulation and its impact on immune cells are not yet fully understood. In treatment, JAK inhibitors have shown therapeutic effectiveness in some patients. Methods: We analyzed clinical presentations, cellular phenotypes, and functional impacts in five Taiwanese patients with STAT1 GOF. Results: We identified two novel GOF mutations in 5 patients from 2 Taiwanese families, presenting with symptoms of CMC, late-onset rosacea, and autoimmunity. The enhanced phosphorylation and delayed dephosphorylation were displayed by the patients' cells. There are alterations in both innate and adaptive immune cells, including expansion of CD38
+ HLADR+ CD8+ T cells, a skewed activated Tfh cells toward Th1, reduction of memory, marginal zone and anergic B cells, all main functional dendritic cell lineages, and a reduction in classical monocyte. Baricitinib showed therapeutic effectiveness without side effects. Conclusion: Our study provides the first comprehensive clinical and molecular characteristics in STAT1 GOF patient in Taiwan and highlights the dysregulated T and B cells subsets which may hinge the autoimmunity in STAT1 GOF patients. It also demonstrated the therapeutic safety and efficacy of baricitinib in pediatric patient. Further research is needed to delineate how the aberrant STAT1 signaling lead to the changes in cellular populations as well as to better link to the clinical manifestations of the disease. [ABSTRACT FROM AUTHOR]- Published
- 2024
- Full Text
- View/download PDF
3. Baseline Demographics, Comorbidities, Treatment Patterns and Burden of Atopic Dermatitis in Adults and Adolescents from the GLOBOSTAD Long-Term Observational Study.
- Author
-
Calzavara-Pinton, Piergiacomo, Čelakovská, Jarmila, Lapeere, Hilde, Holzer, Gregor, Al-Ahmad, Mona, Chu, Chia-Yu, Ferrucci, Silvia M., Kataoka, Yoko, Rossi, Mariateresa, Fomina, Daria S., Chung, Wen-Hung, Tzellos, Thrasyvoulos, Fougerousse, Anne-Claire, Wu, Jiangming, Ardeleanu, Marius, and Ozturk, Zafer E.
- Abstract
Introduction: Insights into real-world treatment of atopic dermatitis (AD) are relevant to clinical decision making. The aim of this analysis was to characterize patients who receive dupilumab for AD in a real-world setting. Methods: The GLOBOSTAD registry is an ongoing, longitudinal, prospective, observational study of patients with AD who receive dupilumab according to country-specific prescribing information. We report baseline characteristics, comorbidities and treatment patterns for patients enrolled from July 11, 2019 to March 31, 2022. Analyses are descriptive; no formal statistical comparisons were performed. Results: Nine hundred fifty-two adults and adolescents were enrolled in GLOBOSTAD. Patients had a high disease burden before starting dupilumab: (mean [standard deviation]) percent body surface area affected (44.8 [24.42]), Eczema Area and Severity Index total score (24.8 [12.95]), SCORing Atopic Dermatitis total score (60.5 [16.34]), Patient-Oriented Eczema Measure total score (19.7 [6.37]) and Dermatology Life Quality Index total score (13.7 [7.02]). Overall, 741 (77.8%) patients reported ≥ 1 type 2 inflammatory comorbidities, most frequently allergic rhinitis (492 [51.7%]), asthma (323 [33.9%]), food allergy (294 [30.9%]) or another allergy (274 [28.8%]). In the previous 12 months, 310 (32.6%) patients had received systemic non-steroidal immunosuppressants and 169 (17.8%) systemic corticosteroids; 449 (47.2%) had received topical corticosteroids, most commonly potent topical corticosteroids; 141 (14.8%) had received topical calcineurin inhibitors and 32 (3.4%) ultraviolet therapy. Most (713 [74.9%]) patients started dupilumab because of prior treatment failure. Conclusion: Patients enrolled in GLOBOSTAD demonstrated considerable multidimensional burden of disease across AD signs, symptoms and quality of life despite previous use of systemic and non-systemic AD treatments. Clinical Trial Registration: ClinicalTrials.gov identifier NCT03992417. 6oUiQE4CT4ZAS7Cewp1A1s Video Abstract [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
4. Advancing Treatment in Bullous Pemphigoid: A Comprehensive Review of Novel Therapeutic Targets and Approaches.
- Author
-
Chen, Hsuan-Chi, Wang, Chuang-Wei, Toh, Wu Han, Lee, Hua-En, Chung, Wen-Hung, and Chen, Chun-Bing
- Abstract
Bullous pemphigoid is one of the most common autoimmune bullous diseases occurring primarily in the elderly. Pathogenic autoantibodies against BP180 and BP230 at the dermal–epidermal junction cause subepidermal blisters, erosions, and intense pruritus, all of which adversely affect the patients' quality of life and may increase their morbidity and mortality. Current systemic treatment options for bullous pemphigoid are limited to corticosteroids and immunosuppressants, which can have substantial side effects on these vulnerable patients that even exceed their therapeutic benefits. Therefore, more precisely, targeting therapies to the pathogenic cells and molecules in bullous pemphigoid is an urgent issue. In this review, we describe the pathophysiology of bullous pemphigoid, focusing on autoantibodies, complements, eosinophils, neutrophils, proteases, and the T helper 2 and 17 axes since they are crucial in promoting proinflammatory environments. We also highlight the emerging therapeutic targets for bullous pemphigoid and their latest discoveries in clinical trials or experimental studies. Further well-designed studies are required to establish the efficacy and safety of these prospective therapeutic options. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
5. New Onset and Exacerbations of Psoriasis Following COVID-19 Vaccines: A Systematic Review.
- Author
-
Wu, Po-Chien, Huang, I-Hsin, Wang, Chuang-Wei, Tsai, Cheng-Chang, Chung, Wen-Hung, and Chen, Chun-Bing
- Subjects
PSORIASIS ,ONLINE information services ,MEDICAL databases ,COVID-19 ,MEDICAL information storage & retrieval systems ,COVID-19 vaccines ,TREATMENT effectiveness ,MEDLINE ,DISEASE exacerbation - Abstract
Background: Vaccination has been promoted to control viral transmission in response to the coronavirus disease 2019 (COVID-19) pandemic. Cases of new-onset or exacerbation of psoriasis, an immune-mediated inflammatory disease, were reported following COVID-19 vaccination. However, a comprehensive review examining the association between COVID-19 vaccination and the occurrence or exacerbation of psoriasis has yet to be performed. Objective: The aim of this systematic review is to investigate the demographics, clinical variables, and outcomes associated with psoriasis following COVID-19 vaccination. Methods: A systematic literature search was conducted using the PubMed, Embase, Web of Science, and Cochrane databases from database inception to April 25, 2022. The review included studies with relevant terms, including 'psoriasis,' 'psoriasis vulgaris,' 'guttate psoriasis,' 'pustular psoriasis,' 'palmoplantar pustulosis,' 'psoriatic erythroderma,' 'psoriatic arthritis,' 'COVID-19,' and 'vaccine.' We included all studies reporting at least one patient who developed new-onset psoriasis or experienced a psoriasis flare following at least one dose of any COVID-19 vaccine. A flare was defined as the worsening of disease conditions after vaccination according to the study by Gregoire et al. The appraisal tool described by Murad et al. was used to assess the quality of case reports and series, whereas the National Institute of Health quality assessment tool was used to assess observational studies. Results: The initial search yielded 367 results, including 7 studies reporting new-onset psoriasis, 32 studies reporting psoriasis flares, and 4 studies reporting both. The most commonly observed psoriasis subtype was plaque-type psoriasis. mRNA vaccines, including those produced by Moderna and BioNTech/Pfizer, were frequently associated with subsequent psoriasis episodes. First, second, and third vaccine doses were associated with psoriasis incidents, with the second dose most frequently associated with psoriasis flares. Delayed onset was observed, ranging from 2 to 21 days in the new-onset group and from 1 to 90 days in the flare group. Most patients experienced favorable outcomes, with improvement or resolution occurring within 3 days to 4 months. Conclusions: Both new-onset psoriasis and psoriasis flares were reported as cutaneous adverse events following COVID-19 vaccination. Psoriatic patients may require regular follow-up before and after COVID-19 vaccination. Trial Registration: Review registration number PROSPERO database: CRD42022304157. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
6. A comparative study of suction blister epidermal grafting and automated blister epidermal micrograft in stable vitiligo.
- Author
-
Gao, Pei-Rong, Wang, Chi-Hui, Lin, Yu-Jr, Huang, Yu-Huei, Chang, Ya-Ching, Chung, Wen-Hung, and Ng, Chau Yee
- Subjects
VITILIGO ,BLISTERS ,TRANSPLANTATION of organs, tissues, etc. ,PATIENTS' attitudes ,COMPARATIVE studies - Abstract
The automated blister epidermal micrograft (ABEM) is a newly introduced surgical transplantation for refractory vitiligo. Comparative analysis of other surgical methods is lacking. We conducted a retrospective study to compare the efficacy, safety, and experience of ABEM with conventional suction blister epidermal graft (SBEG). A total of 118 anatomically based vitiligo lesions from 75 patients were included. The primary outcome was the degree of repigmentation; the patient and operator experience were evaluated. SBEG had a significantly greater incidence of repigmentation (p < 0.001), as measured by the Physician Global Assessment, as well as improvements in the Vitiligo Area Scoring Index, particularly on the face/neck area (p < 0.001). ABEM, on the contrary, had reduced donor harvest time, a better patient operative experience, and more significant Dermatology Life Quality Index improvements. In a subgroup of 38 lesions from ten patients who received both SBEG and ABEM concomitantly, there was no difference in the degree of repigmentation in the same recipient area. Overall, the degree of repigmentation for SBEG is higher than ABEM, especially in the mobilized region, and the cost is less expensive. On the contrary, ABEM requires less procedure learning curve and can supply a greater transplanting zone with shorter donor site recovery. Understanding the benefits and drawbacks of two blister grafting procedures is essential for optimal surgical outcomes for vitiligo grafting. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
7. Mutational signatures and mutagenic impacts associated with betel quid chewing in oral squamous cell carcinoma.
- Author
-
Su, Shih-Chi, Chang, Lun-Ching, Lin, Chiao-Wen, Chen, Mu-Kuan, Yu, Chun-Ping, Chung, Wen-Hung, and Yang, Shun-Fa
- Subjects
SQUAMOUS cell carcinoma ,MUTAGENS ,HETEROZYGOSITY ,TONGUE cancer - Abstract
Betel quid (BQ) chewing is a prevailing risk for oral squamous cell carcinoma (OSCC) in Southeast Asia. Yet, the detailed mechanisms by which BQ chewing damages the genome are still not fully understood. Through exome sequencing of tumor–normal pairs from 196 male patients with OSCC, including 95 habitual BQ chewers and 101 non-BQ users, we conducted a quantitative survey of mutational signatures and genomic aberrations and explored their association with BQ chewing. We found that BQ-associated elevation in mutation rate was seen in cancers of the tongue, but not in overall OSCC. Additionally, we identified a mutational signature that is enriched in tumors from BQ users. Moreover, the numbers of small insertions and deletions (INDELs) and breakpoints derived from structural variations (SV) were increased, whereas the extent of loss of heterozygosity was decreased in BQ-related OSCC genomes. However, neither the number of base substitutions and microsatellite instability events nor the extent of copy-number alterations differed between BQ-related and -unrelated OSCC. In conclusion, consistent with the proposition that BQ chewing increases OSCC risk as a mutagen, our results unveil a BQ-associated mutational signature and indicate mutagenic impacts of BQ chewing on preferentially eliciting INDELs and SV-related breakpoints in OSCC genomes. [ABSTRACT FROM AUTHOR]
- Published
- 2019
- Full Text
- View/download PDF
8. Adverse drug reaction causality assessment tools for drug-induced Stevens-Johnson syndrome and toxic epidermal necrolysis: room for improvement.
- Author
-
Goldman, Jennifer L., Chung, Wen-Hung, Lee, Brian R., Chen, Chun-Bing, Lu, Chun-Wei, Hoetzenecker, Wolfram, Micheletti, Robert, Yasuda, Sally Usdin, Margolis, David J., Shear, Neil H., Struewing, Jeffery P, and Pirmohamed, Munir
- Subjects
- *
COMPARATIVE studies , *COMPUTER software , *DRUG side effects , *STATISTICS , *TOXIC epidermal necrolysis , *INTER-observer reliability , *RESEARCH methodology evaluation , *STEVENS-Johnson Syndrome ,RESEARCH evaluation - Abstract
Purpose: Establishment of causality between drug exposure and adverse drug reactions (ADR) is challenging even for serious ADRs such as Stevens-Johnson syndrome/toxic epidermal necrolysis (SJS/TEN). Several causality assessment tools (CAT) exist, but the reliability and validity of such tools is variable. The objective of this study was to compare the reliability and validity of existing ADR CATs on SJS/TEN cases. Methods: Seven investigators completed three CAT (ALDEN, Naranjo, Liverpool) for 10 SJS/TEN cases. Each CAT categorized the causality of 30 potential drugs as definite/very probable, probable, possible, or doubtful/unlikely. An additional reviewer provided expert opinion by designating the implicated drug(s) for each case. A Kappa score was generated to compare CAT responses both by method (reliability of all 7 reviewers, by CATs) and by reviewer (reliability of the 3 CAT, by reviewer). A c statistic was calculated to assess validity. Results: Inter-rater reliability by CAT was poor to fair: ALDEN 0.22, Naranjo 0.11, and Liverpool 0.12. Reliability was highest when causality classification was definite/very probable (0.16–0.41). Similarly, intra-rater reliability by reviewer was poor. When comparing the validity of the overall CAT to expert reviewer, area under the curve was highest for ALDEN (c statistic 0.65) as compared to Liverpool (0.55) or Naranjo (0.54). Conclusion: Available CAT have poor reliability and validity for drug-induced SJS/TEN. Due to the importance of determining ADR causality for research, industry, and regulatory purposes, development of an enhanced tool that can incorporate data from immunological testing and pharmacogenetic results may strengthen CAT usefulness and applicability for drug-induced SJS/TEN. [ABSTRACT FROM AUTHOR]
- Published
- 2019
- Full Text
- View/download PDF
9. The 10th International Congress on Cutaneous Adverse Drug Reactions, Shimane, Japan, 2018: Focus on New Discoveries.
- Author
-
Olteanu, Cristina, Shear, Neil H., Morita, Eishin, Chung, Wen-Hung, Niihara, Hiroyuki, Matsukura, Setsuko, Hashimoto, Rena, and Dodiuk-Gad, Roni P.
- Subjects
DRUG side effects ,DRUG interactions ,STEVENS-Johnson Syndrome ,PHARMACOGENOMICS - Abstract
The article offers information on the 10th International Congress on Cutaneous Adverse Drug Reactions meeting held on November, 10-11, 2018 at the Shimane Civic Center in Shimane, Japan. Topics discussed include information on the pharmacogenomics discussed by the professor Elizabeth Phillips, Vanderbilt University Medical Center, Nashville; discussions on the Stevens‑Johnson Syndrome and Toxic Epidermal Necrolysis.
- Published
- 2019
- Full Text
- View/download PDF
10. The 9th International Congress on Cutaneous Adverse Drug Reactions at the 23rd World Congress of Dermatology in Vancouver, 2015.
- Author
-
Dodiuk-Gad, Roni, Olteanu, Cristina, Chung, Wen-Hung, Shear, Neil, Dodiuk-Gad, Roni P, and Shear, Neil H
- Subjects
DRUG side effects ,DERMATOLOGY conferences ,PHARMACOGENOMICS ,ADVERSE health care events ,CONFERENCES & conventions - Abstract
The article discusses the highlights of the 9th International Congress on Cutaneous Adverse Drug Reaction held at the 23rd World Congress of Dermatology in Vancouver, British Columbia on June 8, 2015. Neil H. Shear and Wen-Hung Chung served as chairs of the scientific programme, while Roni P. Dodiuk-Gad served as co-chair. Also mentioned are the number of participants and variety of specialists at the event. Pharmacogenomics and cutaneous adverse drug reactions are cited as session topics.
- Published
- 2016
- Full Text
- View/download PDF
11. Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis: An Update.
- Author
-
Dodiuk-Gad, Roni, Chung, Wen-Hung, Valeyrie-Allanore, Laurence, and Shear, Neil
- Subjects
- *
EARLY medical intervention , *TOXIC epidermal necrolysis , *STEVENS-Johnson Syndrome , *DIAGNOSIS - Abstract
Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN) are life-threatening mucocutaneous reactions, predominantly drug induced. The mortality rates for SJS and TEN are as high as 30 %, and short- and long-term morbidities are very common. SJS/TEN is one of the few dermatological diseases that constitute a true medical emergency. Early recognition and prompt and appropriate management can be lifesaving. In recent years, our understanding of the pathogenesis, clinical presentation, and management of SJS/TEN has improved. Nevertheless, in 2015, there are still no internationally accepted management guidelines. This review summarizes up-to-date insights on SJS/TEN and describes a protocol for assessment and treatment. We hope these suggested guidelines serve as a practical clinical tool in the management of SJS/TEN. The classic manifestation of SJS/TEN consists of initial 'flu-like' symptoms (malaise, fever, anorexia) in the prodromal phase, followed by cutaneous and mucous membrane (ocular, oral, and genital) inflammation and pain, and other systemic involvement. Symptoms usually begin 4-28 days after the onset of drug intake. Treatment is multidisciplinary and includes identification and withdrawal of the culprit drug, transfer to a specialist unit, supportive care, medical treatment, communication, and provision of appropriate information and emotional support. [ABSTRACT FROM AUTHOR]
- Published
- 2015
- Full Text
- View/download PDF
12. The (CCTTT) pentanucleotide repeat polymorphism in the inducible nitric oxide synthase gene promoter and the risk of psoriasis in Taiwanese.
- Author
-
Chang, Ya-Ching, Wu, Wei-Ming, Huang, Yu-Huei, Chung, Wen-Hung, Tsai, Hsin-Yi, and Hsu, Lung-An
- Subjects
NITRIC-oxide synthases ,MICROSATELLITE repeats ,GENETIC polymorphisms ,PROMOTERS (Genetics) ,PSORIASIS ,TAIWANESE people ,PATIENTS ,HEALTH - Abstract
Recently, genome-wide association studies identified a novel psoriasis susceptibility locus tagged by two single-nucleotide polymorphisms (SNPs) rs4795067 and rs28998802, both of which are in the intronic region of inducible nitric oxide synthase ( iNOS) gene. This study aimed to assess the role of (CCTTT) pentanucleotide repeat polymorphisms in the promoter region of iNOS gene in Chinese-Taiwanese patients with psoriasis. In total, 280 patients with psoriasis and 512 control subjects were analyzed for the presence of the iNOS microsatellite polymorphism by polymerase chain reactions. The alleles were classified as S and L alleles according to the number of (CCTTT) repeats, with the alleles with ≤13 repeats designated as S and alleles with ≥14 repeats designated as L alleles. The distribution of allele frequencies and genotypes was significantly different between the control and psoriasis groups ( P = 0.040, and 0.014, respectively). After adjustment for age, sex, body mass index, smoking, diabetes, and hypertension, carriers of the LL genotype were 0.38 (95 % confidence interval 0.16-0.95) times less likely than non-carriers to have psoriasis ( P = 0.038). The promoter assays demonstrated that the iNOS promoter activity increases in parallel with the repeat number of (CCTTT) in HaCaT cells. Approximately 70 % of the study subjects were genotyped for rs4795067 and rs28998802. The rs4795067 is in linkage disequilibrium with the microsatellite L/S allelic classification. The association of iNOS microsatellite with psoriasis is independent of these known iNOS variants. Our results suggest that the iNOS microsatellite may contribute to the genetic background of psoriasis in Chinese-Taiwanese patients. [ABSTRACT FROM AUTHOR]
- Published
- 2015
- Full Text
- View/download PDF
13. Carbamazepine and Its Structurally-Related Antiepileptics.
- Author
-
Hung, Shuen-Iu, Chung, Wen-Hung, Tsai, Jing-Jane, and Chen, Yuan-Tsong
- Abstract
Carbamazepine (CBZ) (Equetro
® , Carbatrol® , Epitol® , Tegretol® ) is one of a class of antiepileptic drugs (AEDs) that aim to prevent or reduce the severity of abnormal nerve activity in the brain, thereby blocking seizures [1, 2]. CBZ was initially approved for the treatment of epilepsy in the US in 1974. Currently, the indications for CBZ use include seizures, trigeminal neuralgia, and bipolar disorder [3]. CBZ is now first-line therapy for the treatment of partial seizures and tonic-clonic seizures. The mechanism of action of CBZ antiepileptic effects is thought to be sodium channel blocking, limiting the repetitive firing of action potentials, slowing the rate of recovery of voltage-activated Na+ channels from inactivation, decreasing the activity of nerve cells, and preventing them from firing abnormally in the brain [1, 3]. In addition, CBZ may also prevent abnormal brain signals from spreading to other parts of the brain. Complex partial seizures most frequently arise from the repetitive firing of action potentials in the temporal lobe of the brain and cause impairment of consciousness with or without accompanying automatisms. Patients who have complex partial seizures can be treated with CBZ with a greater response and more significant improvement than patients with other types of seizures [1, 4]. Although CBZ is approved to treat various types of seizures (e.g., partial seizures, generalized tonic-clonic seizures, or mixed seizure patterns), it is usually not -effective at treating absence seizures (petit mal seizures) [5]. [ABSTRACT FROM AUTHOR]- Published
- 2011
- Full Text
- View/download PDF
14. The 8th International Congress on Cutaneous Adverse Drug Reactions, Taiwan, 2013: focus on severe cutaneous adverse reactions.
- Author
-
Dodiuk-Gad, Roni P, Chung, Wen-Hung, Yang, Chih-Hsun, Lu, Chun-Wei, Hui, Rosaline Chung-Yee, and Shear, Neil H
- Published
- 2014
- Full Text
- View/download PDF
15. Combination therapy of focused ultrasound and radio-frequency for noninvasive body contouring in Asians with MRI photographic documentation.
- Author
-
Chang, Shyue-Luen, Huang, Yau-Li, Lee, Mei-Ching, Chang, Chih-Hsiang, Chung, Wen-Hung, Wu, En-Haw, and Hu, Sindy
- Subjects
DIAGNOSTIC ultrasonic imaging ,RADIO frequency ,MAGNETIC resonance imaging ,DENTAL crown contours ,MEDICAL imaging systems ,SELF-realization ,MAGNETIC fields - Abstract
Previous studies have shown that single or multiple treatments by focused ultrasound are effective and safe. However, most include focused ultrasound only and not radio-frequency treatment. There is paucity of magnetic resonance imaging (MRI) measurements and pictures in the literature. This study aimed to assess the efficacy, safety, and pain and satisfaction levels of the combination therapy of focused ultrasound and radio-frequency for improving body contours. Thirty-two Asian patients received 3 sequential treatments every 2 weeks in the abdominal region. Safety parameters and adverse events were recorded. The subjects' pain and satisfaction levels were evaluated using a five-point Likert scale. Two patients underwent MRI study randomly. There was a mean reduction in circumference of 3.91 ± 1.8 cm ( p ≤ 0.001). In MRI measurement, the average in fat thickness reduction was 21.4 and 25 % on the upper and lower abdomen, respectively. There were three mild and self-limited localized adverse events. The satisfaction survey showed that 71.9 % was satisfied with the results, while pain level evaluation showed that 90.5 % felt no pain. Combination therapy of focused ultrasound and radio-frequency for noninvasive body contouring is an effective, safe, and painless procedure in Asians. Although the change is minor compared to traditional surgical procedure, it is real, definite, and effective. [ABSTRACT FROM AUTHOR]
- Published
- 2014
- Full Text
- View/download PDF
16. Cutaneous Normolipemic Plane Xanthoma with Supraglottic Involvement in a Patient with Hand-Schüller-Christian Disease.
- Author
-
Lu, Yueh-Tsung, Chen, Ting-Jui, Chung, Wen-Hung, Kuo, Tseng-Tong, and Hong, Hong-Shang
- Subjects
XANTHOMA ,LANGERHANS cells ,HAND-Schueller-Christian syndrome ,DRUG therapy - Abstract
Normolipemic plane xanthoma fNPX) is a histiocytic disorder characterized by yellow-orange plaques in the periorbital areas, neck, upper trunk, and flexural folds. Association with systemic disease or paraproteinemia has been reported previously, bul rarely with Langerhans cell histiocytosis (LCH). We report a case of Hand-Schüller-Christian disease (a type of LCH) in a patient who developed NPX with supraglottic involvement. NPX developed after several courses of chemotherapy and the supraglottic xanthoma occurred about 2 years later. The coexistence of LCH and non-LCH histiocytic lesions in this patient could be a result of chemotherapy-induced changes or may be just coincidental. [ABSTRACT FROM AUTHOR]
- Published
- 2009
- Full Text
- View/download PDF
17. Correction to: Adverse drug reaction causality assessment tools for drug-induced Stevens-Johnson syndrome and toxic epidermal necrolysis: room for improvement.
- Author
-
Goldman, Jennifer L., Chung, Wen-Hung, Lee, Brian R., Chen, Chun-Bing, Lu, Chun-Wei, Hoetzenecker, Wolfram, Micheletti, Robert, Yasuda, Sally Usdin, Margolis, David J., Shear, Neil H., Struewing, Jeffery P., and Pirmohamed, Munir
- Subjects
- *
TOXIC epidermal necrolysis , *STEVENS-Johnson Syndrome - Abstract
The correct name of the 9th Author is David J. Margolis. The original article was corrected. [ABSTRACT FROM AUTHOR]
- Published
- 2019
- Full Text
- View/download PDF
18. Identification of drug-specific public TCR driving severe cutaneous adverse reactions.
- Author
-
Pan, Ren-You, Chu, Mu-Tzu, Wang, Chuang-Wei, Lee, Yun-Shien, Lemonnier, Francois, Michels, Aaron W., Schutte, Ryan, Ostrov, David A., Chen, Chun-Bing, Phillips, Elizabeth Jane, Mallal, Simon Alexander, Mockenhaupt, Maja, Bellón, Teresa, Tassaneeyakul, Wichittra, White, Katie D., Roujeau, Jean-Claude, Chung, Wen-Hung, and Hung, Shuen-Iu
- Subjects
STEVENS-Johnson Syndrome ,T cell receptors ,CARBAMAZEPINE ,IMMUNE response ,ERYTHEMA - Abstract
Drug hypersensitivity such as severe cutaneous adverse reactions (SCAR), including Stevens–Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN), could be life-threatening. Here, we enroll SCAR patients to investigate the T cell receptor (TCR) repertoire by next-generation sequencing. A public αβTCR is identified from the cytotoxic T lymphocytes of patients with carbamazepine-SJS/TEN, with its expression showing drug/phenotype-specificity and an bias for HLA-B*15:02. This public αβTCR has binding affinity for carbamazepine and its structural analogs, thereby mediating the immune response. Adoptive transfer of T cell expressing this public αβTCR to HLA-B*15:02 transgenic mice receiving oral administration of carbamazepine induces multi-organ injuries and symptoms mimicking SCAR, including hair loss, erythema, increase of inflammatory lymphocytes in the skin and blood, and liver and kidney dysfunction. Our results not only demonstrate an essential role of TCR in the immune synapse mediating SCAR, but also implicate potential clinical applications and development of therapeutics. Severe cutaneous adverse reactions (SCAR) is a T cell-mediated, potentially lethal drug hypersensitivity (DH). Here, the authors identify a carbamazepine-specific TCR common among patients with carbamazepine-induced SCAR that confers SCAR-like pathology in mice upon carbamazepine exposure, thereby implicating specific TCRs in DH etiology. [ABSTRACT FROM AUTHOR]
- Published
- 2019
- Full Text
- View/download PDF
19. Whole-Genome Sequencing of a Family with Hereditary Pulmonary Alveolar Proteinosis Identifies a Rare Structural Variant Involving CSF2RA/CRLF2/IL3RA Gene Disruption.
- Author
-
Chiu, Chih-Yung, Su, Shih-Chi, Fan, Wen-Lang, Lai, Shen-Hao, Tsai, Ming-Han, Chen, Shih-Hsiang, Wong, Kin-Sun, and Chung, Wen-Hung
- Abstract
Pulmonary alveolar proteinosis (PAP) is a rare pulmonary disease in which the abnormalities in alveolar surfactant accumulation are caused by impairments of GM-CSF pathway attributing to defects in a variety of genes. However, hereditary PAP is extremely uncommon and a detailed understanding in the genetic inheritance of PAP in a family may provide timely diagnosis, treatment and proper intervention including genetic consultation. Here, we described a comprehensive analysis of genome and gene expression for a family containing one affected child with a diagnosis of PAP and two other healthy siblings. Family-based whole-genome analysis revealed a homozygous deletion that disrupts CSF2RA, CRLF2, and IL3RA gene in the pseudoautosomal region of the X chromosome in the affected child and one of asymptomatic siblings. Further functional pathway analysis of differentially expressed genes in IL-1β-treated peripheral blood mononuclear cells highlighted the insufficiency of immune response in the child with PAP, especially the protection against bacterial infection. Collectively, our results reveal a novel allele as the genetic determinant of a family with PAP and provide insights into variable expressivity and incomplete penetrance of this rare disease, which will be helpful for proper genetic consultation and prompt treatment to avoid mortality and morbidity. [ABSTRACT FROM AUTHOR]
- Published
- 2017
- Full Text
- View/download PDF
20. Medical genetics: A marker for Stevens-Johnson syndrome.
- Author
-
Chung, Wen-Hung, Hung, Shuen-lu, Hong, Hong-Shang, Hsih, Mo-Song, Yang, Li-Cheng, Ho, Hsin-Chun, Wu, Jer-Yuarn, and Chen, Yuan-Tsong
- Subjects
- *
ALLERGIES , *EPIDERMIS , *GENETIC disorders , *PATHOLOGY , *DRUGS , *IMMUNE response , *HLA histocompatibility antigens - Abstract
Stevens-Johnson syndrome and the related disease toxic epidermal necrolysis are life-threatening reactions of the skin to particular types of medication. Here we show that there is a strong association in Han Chinese between a genetic marker, the human leukocyte antigen HLA-B*1502, and Stevens-Johnson syndrome induced by carbamazepine, a drug commonly prescribed for the treatment of seizures. It should be possible to exploit this association in a highly reliable test to predict severe adverse reaction, as well as for investigation of the pathogenesis of Stevens-Johnson syndrome. [ABSTRACT FROM AUTHOR]
- Published
- 2004
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.